Nutex Health Inc.
NUTX
$44.66
-$1.84-3.96%
| Weiss Ratings | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 3.25 | |||
| Price History | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -19.82% | |||
| 30-Day Total Return | 9.03% | |||
| 60-Day Total Return | 18.02% | |||
| 90-Day Total Return | 81.69% | |||
| Year to Date Total Return | 28.63% | |||
| 1-Year Total Return | 180.09% | |||
| 2-Year Total Return | -81.51% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -33.05% | |||
| 52-Week Low % Change | 1,017.79% | |||
| Price | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $69.45 | |||
| 52-Week Low Price | $4.16 | |||
| 52-Week Low Price (Date) | Jul 10, 2024 | |||
| 52-Week High Price (Date) | Feb 14, 2025 | |||
| Valuation | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 252.82M | |||
| Enterprise Value | 528.49M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -9.76 | |||
| Earnings Per Share Growth | 50.10% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.81 | |||
| Price/Book (Q) | 4.01 | |||
| Enterprise Value/Revenue (TTM) | 1.81 | |||
| Price | $44.66 | |||
| Enterprise Value/EBITDA (TTM) | 14.60 | |||
| Enterprise Value/EBIT | 19.16 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 5.10M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -1.17% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 713 660 0557 | |||
| Address | 6030 South Rice Avenue Houston, TX 77081 | |||
| Website | www.nutexhealth.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 9.44% | |||
| Profit Margin | -14.08% | |||
| Management Effectiveness | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.76% | |||
| Return on Equity | -- | |||
| Income Statement | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 292.00M | |||
| Total Revenue (TTM) | 292.00M | |||
| Revenue Per Share | $57.26 | |||
| Gross Profit (TTM) | 86.22M | |||
| EBITDA (TTM) | 36.20M | |||
| EBIT (TTM) | 27.58M | |||
| Net Income (TTM) | -41.13M | |||
| Net Income Avl. to Common (TTM) | -41.13M | |||
| Total Revenue Growth (Q YOY) | 25.62% | |||
| Earnings Growth (Q YOY) | -58.38% | |||
| EPS Diluted (TTM) | -9.76 | |||
| EPS Diluted Growth (Q YOY) | -37.84% | |||
| Balance Sheet | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 46.91M | |||
| Cash Per Share (Q) | $9.20 | |||
| Total Current Assets (Q) | 119.80M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 79.78M | |||
| Current Ratio (Q) | 1.773 | |||
| Book Value Per Share (Q) | $11.59 | |||
| Total Assets (Q) | 438.49M | |||
| Total Current Liabilities (Q) | 67.56M | |||
| Total Debt (Q) | 303.24M | |||
| Total Liabilities (Q) | 358.71M | |||
| Total Common Equity (Q) | 60.44M | |||
| Cash Flow | NUTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.40M | |||
| Cash from Financing (TTM) | 162.70K | |||
| Net Change in Cash (TTM) | 20.08M | |||
| Levered Free Cash Flow (TTM) | 25.16M | |||
| Cash from Operations (TTM) | 21.32M | |||
